Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Mais filtros

Base de dados
Intervalo de ano de publicação
J Cell Physiol ; 234(4): 5153-5162, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30362512


Overexpression of long noncoding RNA (lncRNA) H19 has been observed in various cancers, which indicates that H19 exert important roles in the progression of carcinogenesis. MiR-326 has been reported to play tumor suppressive roles in multiple tumors. Recently, the competing endogenous RNA (ceRNA) hypothesis has implied that lncRNAs might function as molecular sponges for microRNAs in various cancers. However, the roles of H19/miR-326 in human hepatocellular carcinoma (HCC) still remain unclear. The aim of our study was to determine H19/miR-326 expression in HCC cells and investigate their roles in HCC development. We found that H19 was significantly elevated and miR-326 was decreased in HCC cells including Hep3B, HepG2, MHCC-97L, SK-hep1, Hun7, SMCC-7721 compared with LO2 cells, respectively. In the subsequent experiments, we observed that inhibition of H19 can repress HCC cell growth, migration, and invasion in vitro. H19 downregulation can increase miR-326 expression in HCC cells. Meanwhile, miR-326 mimics can also inhibit HCC progression, whereas miR-326 inhibitors exhibited a reverse phenomenon by modulating H19 expression. In addition, a negative association between H19 and miR-326 was predicted and confirmed. Furthermore, the transcription factor TWIST1 has been recognized as a significant regulator in tumor progression. Here, by performing bioinformatics analysis, TWIST1 was identified as a downstream target of miR-326. The findings of our study implied that lncRNA H19 can serve as a ceRNA to sponge miR-326 and modulate TWIST1 levels in HCC pathogenesis. Taken these together, these findings indicated that H19/miR-326/TWIST1 axis was involved in HCC development and can indicate a novel HCC target.

Clin Interv Aging ; 13: 947-956, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29805253


Background: Little is known about the adverse effects of frailty transitions. In this study, we aimed to characterize the transitions between frailty states and examine their associations with the type of death among older adults in China, a developing country with a rapidly growing aging population. Methods: We used data of 11,165 older adults (aged 65-99 years) from the 2002 and 2005 waves of the Chinese Longitudinal Healthy Longevity Survey (CLHLS). Overall, 44 health deficits were used to construct frailty index (FI; range: 0-1), which was then categorized into a three-level variable: nonfrail (FI ≤0.10), prefrail (0.10< FI ≤0.21), and frail (FI >0.21). Outcome was four types of death based on bedridden days and suffering state (assessed in the 2008 wave of CLHLS). Results: During the 3-year period, 3,394 (30.4%) participants had transitioned between different frailty states (nonfrail, prefrail, and frail), one-third transitioned to death, and one-third remained in previous frailty states. Transitions to greater frailty (ie, "worsening") were more common than transitions to lesser frailty (ie, "improvement"). Among four categories of frailty transitions, "worsening" and "remaining frail" had increased risks of painful death, eg, with odds ratios of 1.92 (95% confidence interval [CI] =1.41, 2.62) and 4.75 (95% CI =3.32, 6.80), respectively, for type 4 death (ie, ≥30 bedridden days with suffering before death). Conclusion: This large sample of older adults in China supports that frailty is a dynamic process, characterized by frequent types of transitions. Furthermore, those who remained frail had the highest likelihood of experiencing painful death, which raises concerns about the quality of life in frail populations.

Idoso Fragilizado/estatística & dados numéricos , Fragilidade/mortalidade , Vigilância da População/métodos , Idoso , Idoso de 80 Anos ou mais , Causas de Morte/tendências , China/epidemiologia , Feminino , Humanos , Longevidade , Masculino , Razão de Chances , Qualidade de Vida , Taxa de Sobrevida/tendências
Drug Des Devel Ther ; 10: 2739-44, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27621595


PURPOSE: To further observe and verify the effect of nonalcoholic fatty liver disease (NAFLD) on the response to antiviral therapy in patients with chronic hepatitis B (CHB) and investigate the relationship between the virologic response and insulin resistance. PATIENTS AND METHODS: A retrospective study was adopted and 61 NAFLD patients with HBeAg-positive CHB were included as the observation group (group A), and 64 patients with simple CHB were included as the control group (group B). RESULTS: After 12 weeks of treatment with entecavir, the total virologic response rate in group A was statistically significantly lower than that in group B (P<0.05). During weeks 24-96, the difference was not statistically significant (P>0.05). In weeks 48 and 96, there was no significant difference in the HBeAg seroconversion rates between the two groups (P>0.05). In weeks 12 and 24, there was also no significant difference in the alanine transaminase (ALT) normalization rate between the two groups (P>0.05). Then, in weeks 48 and 96, the ALT normalization rate of group A was obviously lower than that of group B (P<0.05). Group A patients were divided into group A1 (≤M) and group A2 (>M) according to the median value (M=2.79) of the baseline homeostatic model assessment method insulin resistance levels. In weeks 48 and 96, the ALT normalization rate of group A1 was significantly higher than that of group A2 (P<0.05). The correlation coefficient (r) of the baseline homeostatic model assessment method insulin resistance level and the severity of fatty liver in group A was 0.426 (P=0.001). CONCLUSION: NAFLD cannot affect the long-term total virologic response rate and HBeAg seroconversion rate in CHB patients treated with entecavir but can reduce the long-term biochemical response rate, which has a positive correlation with the severity of fatty liver and the insulin resistance index.

Antivirais/uso terapêutico , Guanina/análogos & derivados , Antígenos E da Hepatite B/metabolismo , Hepatite B Crônica/tratamento farmacológico , Hepatite B Crônica/metabolismo , Resistência à Insulina/fisiologia , Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico , Adolescente , Adulto , Feminino , Guanina/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto Jovem
Exp Ther Med ; 10(1): 269-274, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26170947


The aim of the present study was to investigate the expression of microRNA-218 (miRNA-218) in the serum and cervical tissue and its association with the clinicopathological features of cervical cancer (CC). The expression of miRNA-218 was detected in the serum and cervical tissue of 112 patients with CC and 50 age-matched hysteromyoma patients via the reverse transcription-quantitative polymerase chain reaction. The clinical data were collected and the association between the expression of miRNA-218 and the clinicopathological characteristics of the patients was analyzed. The expression of miRNA-218 in the cancer group was significantly decreased in the cervical tissue and serum compared with that in the control group (P<0.001). The decreased expression of miRNA-218 was associated with a later International Federation of Gynecology and Obstetrics stage, a more invasive pathological type and lymphatic node metastasis but not with age, age at menarche, menopausal status, number of pregnancies and deliveries, family history of cancer or tumor size. In conclusion, miRNA-218 was found to be downregulated in the cancer tissue and serum of the patients with CC. The decreased expression of miRNA-218 in CC was associated with the invasiveness of the tumor.